Jan 21, 2020
Schizophrenia Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027
Oct 23, 2019
Landmark Study Seeks Participants With VCFS-Related Psychosis to Help Create Biobank of Human Neural Tissue to Develop Innovative Treatments
Oct 09, 2019
NEURO-PAIN MEDICAL CENTER is Recruiting for Clinical Study to Evaluate Investigational Drug for Parkinson's
Oct 01, 2019
SEP361-203 Study Evaluating an Investigational Medication in People With Parkinson's Disease Experiencing Hallucinations and Delusions
Jul 19, 2019
Parkinson's Disease Market and Behavioral Complications: Top 351 Key Companies, Innovation, and Future Outlook to 2026
May 09, 2019
VeraSci Welcomes William P. Horan, PhD as VP of Clinical Science
May 06, 2019
Neurocrine Biosciences Honors Mental Health Month and Raises Awareness of Tardive Dyskinesia and its Impact on Patients
Jan 31, 2019
Top 12 Advances in Psychiatric Research in 2018 from the Brain & Behavior Research Foundation
Jan 16, 2019
New INGREZZA® (valbenazine) Analysis Published in the Journal of Affective Disorders Demonstrates Sustained Improvement in Tardive Dyskinesia Symptoms in Patients with Primary Mood Disorders
Nov 05, 2018
Researchers use genetics to predict response to antipsychotic medications
Jul 16, 2018
Schizophrenia Drugs Market Growth Analysis, Insights and Regional Outlook 2025 Forecast Report | ReportsnReports
Jun 14, 2018
Selección Nacional de México Joins Paranoid Fan to Deploy Emoji Maps
Jun 08, 2018
Schizophrenia Frontier Pharma Report 2018: A Complex and Poorly Understood Disorder with Numerous Unmet Needs
Mar 12, 2018
Global Schizophrenia Treatment Market to Reach US$ 2600 Mn by 2027 - Persistence Market Research
Feb 09, 2018
Boehringer Ingelheim refocuses PDE9 inhibition brain research on schizophrenia following results from Phase II Alzheimer's trials
Jan 25, 2018
AB InBev-Backed Mapping App, Paranoid Fan, To Launch Emoji Maps With Prizes For Super Bowl LII
Nov 10, 2017
Rising Competition for Treating Positive Symptoms of Schizophrenia Requires Companies to Focus on Therapies for Negative and Cognitive Symptoms
Oct 27, 2017
Relmada Therapeutics Announces Notice of Acceptance of Key Patent in Australia Covering NMDA Receptor Antagonist d-Methadone for Treatment of Psychiatric Symptoms
Aug 03, 2017
Medical Marijuana, Inc. Major Investment AXIM Biotech Enters Clinical Study Agreement with University of British Columbia to Begin Clinical Trial On CBD Chewing Gum For Treatment of Drug-Related Psychosis
Jul 21, 2017
IBM and University of Alberta publish new data on machine learning algorithms to help predict schizophrenia